Loading…
HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions
Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen ( HLA ) alleles are associated with XST-relate...
Saved in:
| Published in: | The pharmacogenomics journal 2019-06, Vol.19 (3), p.277-285 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3 |
| container_end_page | 285 |
| container_issue | 3 |
| container_start_page | 277 |
| container_title | The pharmacogenomics journal |
| container_volume | 19 |
| creator | Yan, Sijia Xiong, Hao Shao, Fengmin Zhang, Wen Yang, Fanping Qi, Zheng Chen, Shengan He, Lin Jiang, Menglin Su, Yu Zhu, Huizhong Qin, Shengying Zhu, Qinyuan Luo, Xiaoqun Xing, Qinghe |
| description | Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (
HLA
) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried
HLA-C*12:02
, and all of them received XST via intravenous drip. The carrier frequency of
HLA-C*12:02
was significantly high compare to that of the control population (Pc = 4.4 × 10
−4
, odds ratio (OR) = 21.75, 95% CI = 5.78–81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58–282.98). The results suggest that
HLA-C*12:02
is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip. |
| doi_str_mv | 10.1038/s41397-018-0051-3 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2228647856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A586271008</galeid><sourcerecordid>A586271008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3</originalsourceid><addsrcrecordid>eNp1kVFrVDEQhYNUbK3-AF_kQp9TZ5Lc3KRvy1KtsOCLQvElZJPcNWX3pia5LfvvTd1qESp5SJg5Z-aEj5B3COcIXH0oArkeKKCiAD1S_oKcoBg4Rezh6PcbKJP6-pi8LuUGACUO6hU55sD40Ct2Qr5frRZ0iewCWBdLV2pO02a772wpyUVbg-_uY_3RXc-h2Fhbk8bJz67V3VztFNJcOuvvQi6h83nedDlYV2OayhvycrTbEt4-3qfk28fLr8sruvry6fNysaJOcF1piyGZ11r0YdSK6QGlHR14Lb0XDtZCrPvAx7XwoKUCpTSg9jhIDwyd8_yUnB3m3ub0s8Ws5ibNeWorDWNMSTGoXj6pNnYbTJzGVLN1u1icWfRKsgEBVFOdP6Nqx4dddGkKY2z1fwx4MLicSslhNLc57mzeGwTzAMkcIJkGyTxAMrx53j8Gnte74P86_lBpAnYQlNaaNiE__ej_U38BBYGZ2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2228647856</pqid></control><display><type>article</type><title>HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions</title><source>Springer Link</source><creator>Yan, Sijia ; Xiong, Hao ; Shao, Fengmin ; Zhang, Wen ; Yang, Fanping ; Qi, Zheng ; Chen, Shengan ; He, Lin ; Jiang, Menglin ; Su, Yu ; Zhu, Huizhong ; Qin, Shengying ; Zhu, Qinyuan ; Luo, Xiaoqun ; Xing, Qinghe</creator><creatorcontrib>Yan, Sijia ; Xiong, Hao ; Shao, Fengmin ; Zhang, Wen ; Yang, Fanping ; Qi, Zheng ; Chen, Shengan ; He, Lin ; Jiang, Menglin ; Su, Yu ; Zhu, Huizhong ; Qin, Shengying ; Zhu, Qinyuan ; Luo, Xiaoqun ; Xing, Qinghe</creatorcontrib><description>Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (
HLA
) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried
HLA-C*12:02
, and all of them received XST via intravenous drip. The carrier frequency of
HLA-C*12:02
was significantly high compare to that of the control population (Pc = 4.4 × 10
−4
, odds ratio (OR) = 21.75, 95% CI = 5.78–81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58–282.98). The results suggest that
HLA-C*12:02
is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/s41397-018-0051-3</identifier><identifier>PMID: 30237582</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>45 ; 45/77 ; 631/208/212/1728 ; 692/53/2423 ; Adult ; Adverse and side effects ; Aged ; Aged, 80 and over ; Alleles ; Antigens ; Asians - genetics ; Biomedical and Life Sciences ; Biomedicine ; Cardiovascular disease ; Carrier frequencies ; Cerebrovascular diseases ; Dermatology ; Drug Eruptions - genetics ; Drug-Related Side Effects and Adverse Reactions - genetics ; Drugs ; Drugs, Chinese Herbal - adverse effects ; Erythema ; Female ; Gene Expression ; Gene Frequency - genetics ; Genetic Predisposition to Disease - genetics ; Genotype ; Histocompatibility antigen HLA ; HLA-C Antigens - genetics ; Hospitals ; Human Genetics ; Humans ; Intravenous administration ; Male ; Membrane proteins ; Middle Aged ; Oncology ; Pathogenicity ; Pathogens ; Patients ; Pharmacotherapy ; Population ; Population genetics ; Psychopharmacology ; Risk factors ; Saponins - adverse effects ; Side effects ; Urticaria ; Values ; Vascular diseases ; Young Adult</subject><ispartof>The pharmacogenomics journal, 2019-06, Vol.19 (3), p.277-285</ispartof><rights>Springer Nature Limited 2018</rights><rights>COPYRIGHT 2019 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3</citedby><cites>FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30237582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Sijia</creatorcontrib><creatorcontrib>Xiong, Hao</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><creatorcontrib>Zhang, Wen</creatorcontrib><creatorcontrib>Yang, Fanping</creatorcontrib><creatorcontrib>Qi, Zheng</creatorcontrib><creatorcontrib>Chen, Shengan</creatorcontrib><creatorcontrib>He, Lin</creatorcontrib><creatorcontrib>Jiang, Menglin</creatorcontrib><creatorcontrib>Su, Yu</creatorcontrib><creatorcontrib>Zhu, Huizhong</creatorcontrib><creatorcontrib>Qin, Shengying</creatorcontrib><creatorcontrib>Zhu, Qinyuan</creatorcontrib><creatorcontrib>Luo, Xiaoqun</creatorcontrib><creatorcontrib>Xing, Qinghe</creatorcontrib><title>HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (
HLA
) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried
HLA-C*12:02
, and all of them received XST via intravenous drip. The carrier frequency of
HLA-C*12:02
was significantly high compare to that of the control population (Pc = 4.4 × 10
−4
, odds ratio (OR) = 21.75, 95% CI = 5.78–81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58–282.98). The results suggest that
HLA-C*12:02
is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip.</description><subject>45</subject><subject>45/77</subject><subject>631/208/212/1728</subject><subject>692/53/2423</subject><subject>Adult</subject><subject>Adverse and side effects</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alleles</subject><subject>Antigens</subject><subject>Asians - genetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cardiovascular disease</subject><subject>Carrier frequencies</subject><subject>Cerebrovascular diseases</subject><subject>Dermatology</subject><subject>Drug Eruptions - genetics</subject><subject>Drug-Related Side Effects and Adverse Reactions - genetics</subject><subject>Drugs</subject><subject>Drugs, Chinese Herbal - adverse effects</subject><subject>Erythema</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Frequency - genetics</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genotype</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-C Antigens - genetics</subject><subject>Hospitals</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Intravenous administration</subject><subject>Male</subject><subject>Membrane proteins</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Pathogenicity</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Pharmacotherapy</subject><subject>Population</subject><subject>Population genetics</subject><subject>Psychopharmacology</subject><subject>Risk factors</subject><subject>Saponins - adverse effects</subject><subject>Side effects</subject><subject>Urticaria</subject><subject>Values</subject><subject>Vascular diseases</subject><subject>Young Adult</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kVFrVDEQhYNUbK3-AF_kQp9TZ5Lc3KRvy1KtsOCLQvElZJPcNWX3pia5LfvvTd1qESp5SJg5Z-aEj5B3COcIXH0oArkeKKCiAD1S_oKcoBg4Rezh6PcbKJP6-pi8LuUGACUO6hU55sD40Ct2Qr5frRZ0iewCWBdLV2pO02a772wpyUVbg-_uY_3RXc-h2Fhbk8bJz67V3VztFNJcOuvvQi6h83nedDlYV2OayhvycrTbEt4-3qfk28fLr8sruvry6fNysaJOcF1piyGZ11r0YdSK6QGlHR14Lb0XDtZCrPvAx7XwoKUCpTSg9jhIDwyd8_yUnB3m3ub0s8Ws5ibNeWorDWNMSTGoXj6pNnYbTJzGVLN1u1icWfRKsgEBVFOdP6Nqx4dddGkKY2z1fwx4MLicSslhNLc57mzeGwTzAMkcIJkGyTxAMrx53j8Gnte74P86_lBpAnYQlNaaNiE__ej_U38BBYGZ2A</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Yan, Sijia</creator><creator>Xiong, Hao</creator><creator>Shao, Fengmin</creator><creator>Zhang, Wen</creator><creator>Yang, Fanping</creator><creator>Qi, Zheng</creator><creator>Chen, Shengan</creator><creator>He, Lin</creator><creator>Jiang, Menglin</creator><creator>Su, Yu</creator><creator>Zhu, Huizhong</creator><creator>Qin, Shengying</creator><creator>Zhu, Qinyuan</creator><creator>Luo, Xiaoqun</creator><creator>Xing, Qinghe</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope></search><sort><creationdate>20190601</creationdate><title>HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions</title><author>Yan, Sijia ; Xiong, Hao ; Shao, Fengmin ; Zhang, Wen ; Yang, Fanping ; Qi, Zheng ; Chen, Shengan ; He, Lin ; Jiang, Menglin ; Su, Yu ; Zhu, Huizhong ; Qin, Shengying ; Zhu, Qinyuan ; Luo, Xiaoqun ; Xing, Qinghe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>45</topic><topic>45/77</topic><topic>631/208/212/1728</topic><topic>692/53/2423</topic><topic>Adult</topic><topic>Adverse and side effects</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alleles</topic><topic>Antigens</topic><topic>Asians - genetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cardiovascular disease</topic><topic>Carrier frequencies</topic><topic>Cerebrovascular diseases</topic><topic>Dermatology</topic><topic>Drug Eruptions - genetics</topic><topic>Drug-Related Side Effects and Adverse Reactions - genetics</topic><topic>Drugs</topic><topic>Drugs, Chinese Herbal - adverse effects</topic><topic>Erythema</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Frequency - genetics</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genotype</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-C Antigens - genetics</topic><topic>Hospitals</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Intravenous administration</topic><topic>Male</topic><topic>Membrane proteins</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Pathogenicity</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Pharmacotherapy</topic><topic>Population</topic><topic>Population genetics</topic><topic>Psychopharmacology</topic><topic>Risk factors</topic><topic>Saponins - adverse effects</topic><topic>Side effects</topic><topic>Urticaria</topic><topic>Values</topic><topic>Vascular diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Sijia</creatorcontrib><creatorcontrib>Xiong, Hao</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><creatorcontrib>Zhang, Wen</creatorcontrib><creatorcontrib>Yang, Fanping</creatorcontrib><creatorcontrib>Qi, Zheng</creatorcontrib><creatorcontrib>Chen, Shengan</creatorcontrib><creatorcontrib>He, Lin</creatorcontrib><creatorcontrib>Jiang, Menglin</creatorcontrib><creatorcontrib>Su, Yu</creatorcontrib><creatorcontrib>Zhu, Huizhong</creatorcontrib><creatorcontrib>Qin, Shengying</creatorcontrib><creatorcontrib>Zhu, Qinyuan</creatorcontrib><creatorcontrib>Luo, Xiaoqun</creatorcontrib><creatorcontrib>Xing, Qinghe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Sijia</au><au>Xiong, Hao</au><au>Shao, Fengmin</au><au>Zhang, Wen</au><au>Yang, Fanping</au><au>Qi, Zheng</au><au>Chen, Shengan</au><au>He, Lin</au><au>Jiang, Menglin</au><au>Su, Yu</au><au>Zhu, Huizhong</au><au>Qin, Shengying</au><au>Zhu, Qinyuan</au><au>Luo, Xiaoqun</au><au>Xing, Qinghe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>19</volume><issue>3</issue><spage>277</spage><epage>285</epage><pages>277-285</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (
HLA
) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried
HLA-C*12:02
, and all of them received XST via intravenous drip. The carrier frequency of
HLA-C*12:02
was significantly high compare to that of the control population (Pc = 4.4 × 10
−4
, odds ratio (OR) = 21.75, 95% CI = 5.78–81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58–282.98). The results suggest that
HLA-C*12:02
is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30237582</pmid><doi>10.1038/s41397-018-0051-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2019-06, Vol.19 (3), p.277-285 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_proquest_journals_2228647856 |
| source | Springer Link |
| subjects | 45 45/77 631/208/212/1728 692/53/2423 Adult Adverse and side effects Aged Aged, 80 and over Alleles Antigens Asians - genetics Biomedical and Life Sciences Biomedicine Cardiovascular disease Carrier frequencies Cerebrovascular diseases Dermatology Drug Eruptions - genetics Drug-Related Side Effects and Adverse Reactions - genetics Drugs Drugs, Chinese Herbal - adverse effects Erythema Female Gene Expression Gene Frequency - genetics Genetic Predisposition to Disease - genetics Genotype Histocompatibility antigen HLA HLA-C Antigens - genetics Hospitals Human Genetics Humans Intravenous administration Male Membrane proteins Middle Aged Oncology Pathogenicity Pathogens Patients Pharmacotherapy Population Population genetics Psychopharmacology Risk factors Saponins - adverse effects Side effects Urticaria Values Vascular diseases Young Adult |
| title | HLA-C12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A19%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-C12:02%20is%20strongly%20associated%20with%20Xuesaitong-induced%20cutaneous%20adverse%20drug%20reactions&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Yan,%20Sijia&rft.date=2019-06-01&rft.volume=19&rft.issue=3&rft.spage=277&rft.epage=285&rft.pages=277-285&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/s41397-018-0051-3&rft_dat=%3Cgale_proqu%3EA586271008%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-58262d9945ef9829716afc0d96dd4c0b44b5e3fb4d09680889019d176d021ccd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2228647856&rft_id=info:pmid/30237582&rft_galeid=A586271008&rfr_iscdi=true |